Company Encyclopedia
View More
name
Abeona Therap
ABEO.US
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.
1.935 T
ABEO.USMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking126/401
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE75.90%A
    • Profit Margin20587.50%A
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY0.00%C
    • Net Profit YoY215.93%A
    • Total Assets YoY91.63%A
    • Net Assets YoY274.09%A
  • Cash ScoreC
    • Cash Flow Margin0.49%C
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio25.90%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ABEO Secures 90.84% Stake in VOGO After Reopened Offer

    ABEO has acquired a 90.84% stake in VOGO after reopening its offer, solidifying its majority position. The transaction results were announced by VOGO.

    Reuters·
    US
    ABEO
    +0.74%
    Reuters·
    US
    ABEO
    +0.74%

    Abeona Therapeutics Appoints Mohamad Tabrizi as Chief Business Officer

    Abeona Therapeutics Inc. has appointed Mohamad Tabrizi as Senior Vice President and Chief Business Officer. Tabrizi will lead corporate strategy, business development, and operational efficiency. He brings experience from venture capital, corporate development, and investment banking. This appointment was announced via GlobeNewswire on December 15, 2025.

    Reuters·
    US
    ABEO
    +0.74%
    Reuters·
    US
    ABEO
    +0.74%

    AWM Investment Company Inc. Acquires New Shares in Abeona Therapeutics Inc. $ABEO

    AWM Investment Company Inc. acquired 470,000 shares in Abeona Therapeutics Inc., valued at $2,670,000, owning 0.92% of the company. Analysts have mixed ratings, with a consensus price target of $20.00. Abeona's stock opened at $5.36, with a market cap of $290.46 million. Insiders sold shares worth $410,271 recently.

    Market Beat·
    US
    ABEO
    +0.74%
    Market Beat·
    US
    ABEO
    +0.74%

    Abeona Therapeutics Treats First Patient With FDA-Approved ZEVASKYN Gene Therapy

    Abeona Therapeutics Inc. has treated the first patient with ZEVASKYN, the FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN uses genetically modified skin cells to produce type VII collagen, promoting wound healing. The therapy showed significant wound healing and pain reduction after one application. More patients are scheduled for treatment soon. This marks a major milestone in gene therapy for RDEB.

    Reuters·
    US
    ABEO
    +0.74%
    Reuters·
    US
    ABEO
    +0.74%

    ABEO Acquires 86.43% Stake in VOGO

    ABEO has acquired an 86.43% stake in VOGO following a successful public offer, as disclosed by VOGO. This marks a significant corporate event for both companies.

    Reuters·
    US
    ABEO
    +0.74%
    Reuters·
    US
    ABEO
    +0.74%
    © 2025 Longbridge｜Disclaimer